Redcare Pharmacy N.V.

Investor Presentation • May 22, 2022

BERENBERG CONFERENCE USA 2022.

23 & 24 MAY

PRESENTING EUROPE'S LEADING CUSTOMER-CENTRIC E-PHARMACY PLATFORM.

SHOP APOTHEKE EUROPE AT A GLANCE.

COMBINING OTC, BPC & RX OFFERINGS.

SERVING ALL AGE GROUPS.

LEADERSHIP POSITION IN EUROPE.

7 COUNTRIES.

8,3 MILLION CUSTOMERS.

1,800 EMPLOYEES.

OFFICE HUBS IN SEVENUM, COLOGNE. BERLIN, MUNICH, WARSAW AND MILAN.

5

OUR GOAL.

SIGNIFICANT OPPORTUNITY.

THE GOLD STANDARD FOR CUSTOMER EXPERIENCE.

7

Improving customer experience based on our state-of-the-art technology platform is a key competitive advantage of our business model.

• Possibility to quickly respond to latest developments in e-commerce. • Rapid deployment of new features to further improve customer experience. • Fast and secure connectivity of partner OUR COMPETITIVE ADVANTAGE. RUNNING RELEVANT DIGITAL TECHNOLOGY IN-HOUSE.

-

• systems.

OFFERING A WORLD OF HEALTH TO EVERYONE.

A GOOD FOUNDATION FOR: INTACT LONG-TERM GROWTH PROSPECTS.

BEAUTY AND

FUNCTIONAL FOOD AND NUTRITION

Rx

OWN BRANDS

THE E-RX OPPORTUNITY IN GERMANY.

E-PRESCRIPTION PROGRESS & OUTLOOK.

• 30,000 e-prescriptions have to be processed during the test phase before broader rollout; half-way mark passed in May.
• Details of rollout to be decided and announced following
• Gematik shareholders' meeting at the end of May 2022. Shop Apotheke Europe is ready for e-prescriptions and has been processing them successfully since October 2021.
• We recently strengthened our preparedness for the rollout by acquiring quick-commerce delivery business FIRST A.

• PRODUCT CARBON FOOTPRINT, • PRIVACY & DATA SECURITY, • PRODUCT SAFETY & QUALITY, • GOVERNANCE, • LABOR MANAGEMENT. • INCREASED FROM 5.0 POINTS TO 8.1 POINTS. LATEST NEWS FROM MSCI.

• IMPROVEMENT IN THESE SCORES:
  -
  -
  -
  -

.

-

UPGRADED TO AA RATING.

APPENDIX.

HIGHLIGHTS.

• DOUBLE-DIGIT GROWTH IN EVERYTHING-BUT-RX CONTINUES.

UP 15%, ON TRACK FOR FULL-YEAR GUIDANCE WITH SIGNIFICANT MARKET SHARE GAINS. RX SALES STABLE QUARTER-OVER-QUARTER.

• ADJ. EBITDA EUR -4M.

MARGIN AT -1.4%, 2.1PP BETTER THAN PRIOR Q4. ON TRACK FOR FULL YEAR GUIDANCE –OFFSETTING IMPACT OF A MORE CHALLENGING ENVIRONMENT.

• OPERATING CASH FLOW EUR +24M.

CONTINUED FAVOURABLE WORKING CAPITAL MOVEMENTS.

• RECORD CUSTOMER SATISFACTION AND HIGH GROWTH OF NEW CUSTOMERS CONTINUED.

NPS 73, DRIVEN BY SUCCESSES FROM OUR NEW FACILITY. ACTIVE CUSTOMER BASE 8.3M: UP 0.4M IN Q1 AND 1.5M YOY.

• E-RX GEMATIK TEST ACCELERATES.

APPROACHING 50% OF THE REQUIRED 30,000 SUCCESSFUL ORDERS.

• ACQUISITION OF QUICK-COMMERCE FIRST A. DELIVERY WITHIN 30 MINUTES IN COOPERATION WITH LOCAL PHARMACIES.

KEY FINANCIALS. DACH / EVERYTHING-BUT-RX +10%, INTERNATIONAL UP +30%.

KEY FINANCIALS. 2021: EUR 1,060M SALES AND EUR -5M (-0.5%) ADJ. EBITDA.

						18
KEY FINANCIALS.
2021: EUR 1,060M SALES AND EUR -5M (-0.5%) ADJ. EBITDA.
Adjusted numbers in million of euros	Q1 2022 YTD			Full Year 2021 Q3
			Better/			Better/
		Q1 2022		2020	2021	(Worse)
	Q1 2021		(Worse)
Sales	284	305	7.3%	968	1,060	9.5%
- Everything-but-Rx (Non-Rx)	239	275	15%	749	917	22.5%
- Rx	45.1	30.4	(32.6%)	219	144	(34.6%)
Gross profit margin	25.6%	26.6%	1.0 pp	22.7%	25.2%	2.5 pp
Selling & distribution as percentage of sales	-20.7%	-25.0%	(4.3) pp	-17.8%	-22.6%	(4.8) pp
Administrative costs as percentage of sales	-2.9%	-2.9%	0.0 pp	-2.7%	-3.1%	(0.4) pp
Adj. EBITDA	5.7	-4.3	(10)	22	-5	(27)
Adj. EBITDA margin	2.0%	-1.4%	(3.4) pp	2.2%	-0.5%	(2.7) pp

KEY FINANCIALS. ROBUST CASH POSITION.